Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10502202 | 0.98 | OPRD1 (0.48) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| SCHEMBL863351 | 0.93 | OPRD1 (0.44) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| SCHEMBL11254844 | 0.89 | OPRD1 (0.43) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| SCHEMBL29418152 | 0.89 | OPRD1 (0.43) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| Hydrochloric Acid SCHEMBL3226548 | 0.88 | OPRD1 (0.42) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| SCHEMBL22032186 | 0.86 | SIGMAR1 (0.44) | OPRD1HTR2CKCNH2CYP2D6TSHR | |
| SCHEMBL30538343 | 0.85 | SIGMAR1 (0.53) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| SCHEMBL471621 | 0.85 | SIGMAR1 (0.53) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| Hydrochloric Acid SCHEMBL2345566 | 0.84 | SIGMAR1 (0.51) | OPRD1HTR2CHTR2BKCNH2OPRK1 | |
| SCHEMBL7858958 | 0.82 | SIGMAR1 (0.41) | CYP2D6TSHRCYP2C19CYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | claimed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | claimed |
| EP-3772513-A1 | SHP2 INHIBITORS | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2021-02-10 | — | — | EP | claimed |
| EP-2120935-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008103126-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | claimed |
| EP-0351282-B1 | (1-Hydroxy-2-piperidinyl alkyl)-2-indolone, 2-quinolinones, 2-benzo[b]azepinone, 2-benzimidazolone and 2-quinazolinone derivatives, their preparation and therapeutical use | SYNTHELABO (FR) | 1993-10-27 | — | — | EP | claimed |
| US-5034401-A | Cardiovascular disorders or antiischemia agents | SYNTHELABO (FR) | 1991-07-23 | — | — | US | claimed |
| EP-0104632-A2 | 1'-(3-(1,2-Benzisoxazol-3-yl)propyl)spiro-(benzofuran-2-(3H),3' or 4'-piperidine or 3'-pyrrolidines), a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-04-04 | — | — | EP | claimed |
| US-4166119-A | Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines | AMERICAN HOECHST CORPORATION (US) | 1979-08-28 | — | — | US | claimed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12448392-B2 | Spiropiperidine derivatives | CEPHALON LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-119462695-A | Pyridine derivative and application thereof | 康百达（四川）生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113795483-B | Carboxamide-pyrimidine derivatives as SHP2 antagonists | 默克专利有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-0004951-B1 | N-(3-BENZOYLPROPYL)-SPIRO-(DIHYDROBENZOFURANPIPERIDINES AND -PYRROLIDINES), DERIVATIVES THEREOF, METHODS FOR THEIR PREPARATION AND THEIR USE FOR MEDICINES | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-01-13 | — | — | EP | disclosed |
| EP-0004951-A1 | N-(3-benzoylpropyl)-spiro-(dihydrobenzofuranpiperidines and -pyrrolidines), derivatives thereof, methods for their preparation and their use for medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-31 | — | — | EP | disclosed |
| EP-0004952-A1 | Spiro-(dihydrobenzofuranpiperidines and -pyrrolidines) and derivatives thereof, methods for their preparation and medicines containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-10-31 | — | — | EP | disclosed |
| US-4166120-A | Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines | AMERICAN HOECHST CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
| US-4166119-A | Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines | AMERICAN HOECHST CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | OPRD1 4416/4885HTR2C 4664/4885HTR2B 4716/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | OPRD1 9/4885HTR2C 22/4885HTR2B 96/4885 |
| US-12448392-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | OPRD1 1438/4885HTR2C 1912/4885HTR2B 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.